Clinical trials: H Pylori Infection
Helicobacter Pylori Infection
Comparing the Efficacy of Reverse Hybrid Therapy and Bismuth Quadruple Therapy
Reverse hybrid therapy achieves a higher eradication rate than bismuth quadruple therapy remained unanswered.
- Trial name
- NCT02547038
- Testing
- pantoprazole+bismuth+tetra+metro, (panto+amox+clar+metr)+(panto+amox)
- Where
- Taiwan
- Volunteers
- 352 people
- Sponsor
- Kaohsiung Veterans General Hospital.
H. Pylori Infection
ARJ C13 Urea Breath Test System
An open-label, comparative group study to evaluate the equivalency of the PyloPlus 13C Urea Breath Test to predicate devices on the market.
- Trial name
- NCT04036838
- Testing
- PyloPlus UBT System, Histology, Rapid Urease Test
- Where
- 6 sites in United States
- Volunteers
- 415 people
- Sponsor
- ARJ Medical, Inc.
Helicobacter Pylori Infection
13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)
Approximately 200 patients with suspected H.pylori will be tested with a 13C-Urea Breath Test (UBT) to ascertain H.pylori positive.
- Trial name
- NCT00825630
- Testing
- Lansoprazole (Lanton), Omeprezole (Losec), Pantoprazole(Controloc)
- Where
- Israel
- Volunteers
- 123 people
- Sponsor
- Meridian Bioscience, Inc.
Helicobacter Pylori Infection
Exalenz Lab Mode System Compared to Biopsy for H.Pylori Detection
The Exalenz Dual Mode BreathID® Hp System comprised of IDkit: Hp™ TWO and the Dual Mode BreathID® Hp test device will be used to perform a urea breath test in the initial diagnosis and post treatment monitoring of H.pylori…
- Trial name
- NCT02528721
- Testing
- Dual Mode BreathID Hp System
- Where
- 13 sites in United States, Israel
- Volunteers
- 282 people
- Sponsor
- Meridian Bioscience, Inc.
Helicobacter Infection
Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection
Helicobacter pylori is a bacteria that infects the lining of the stomach and is associated with ulcers. Helicobacter pylori may also increase the long-term risk of developing certain forms of gastric cancer.
- Trial name
- 960025 (NCT00656968)
- Testing
- 10-day sequential treatment, 10-day concomitant therapy
- Where
- 2 sites in Taiwan
- Volunteers
- 232 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Erosive Esophagitis, Heartburn
A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily
The primary objective is to determine the pharmacokinetics (PK) of vonoprazan in breast milk of healthy lactating women who have received vonoprazan administered once daily or vonoprazan 20 mg administered twice daily for 4…
- Conditions
- Erosive Esophagitis, Heartburn, Symptomatic Nonerosive Gasroesophageal Reflux Disease, Helicobacter Pylori Infection
- Trial name
- NCT06391177
- Testing
- Vonoprazan
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Phathom Pharmaceuticals, Inc.
Helicobacter Pylori Infection
Safety and Efficacy Study of a Non-antibiotic Treatment for the Eradication of Helicobacter Pylori
At present, triple therapy is recommended by various guidelines for the treatment of Helicobacter pylori (H.pylori) infection. Recent studies have shown increasing resistance of H.pylori to commonly used antibiotics used in…
- Trial name
- NCT01109381
- Testing
- GT08
- Where
- Singapore
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Synergy Pharmaceuticals Pte. Ltd.
Gastric Ulcer
Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection
The purpose of this study is to demonstrate the non-inferior efficacy of TAK-438 versus lansoprazole in the treatment of participants with gastric ulcer.
- Trial name
- NCT03050307
- Testing
- TAK-438, Lansoprazole, Bismuth-Containing Quadruple Therapy
- Where
- 81 sites in China, Philippines and 2 more
- Volunteers
- 234 people
- Sponsor
- Takeda
Helicobacter Pylori Infection
Comparison of Hybrid and Bismuth Quadruple Therapies for Helicobacter Pylori Eradication
According the Maastricht IV consensus report publish in the Gut 2012, bismuth containing quadruple therapy was suggested to be the first choice for eradication therapy of Helicobacter pylori in the area with high clarithromycin…
- Trial name
- NCT02541864
- Testing
- Bismuth quadruple therapy, Hybrid therapy
- Volunteers
- 330 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Helicobacter Pylori Infection
Comparing the Efficacy of Reverse Hybrid Therapy and Concomitant Therapy
Reverse hybrid therapy achieves a higher eradication rate than concomitant therapy remains unanswered.
- Trial name
- NCT02646332
- Testing
- (dexlan+amox+clar+metr)+(dexlan+amox), dexlan+clarith+amox+metro
- Where
- Taiwan
- Volunteers
- 248 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Helicobacter Pylori Infection
A Phase 1 Study to Evaluate PK Profile of Multiple Oral Administrations of TNP-2092 Capsules in Healthy Subjects
This study was a single-center, randomized, double-blind, placebo-controlled, dose-ascending multiple-dose-administration study.
- Trial name
- NCT06190340
- Testing
- TNP-2092 capsules
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- TenNor Therapeutics (Suzhou) Limited
Peptic Ulcer, Helicobacter Pylori Infection
Clarithromycin Resistant Tailored Therapy
1. Back ground Antibiotics resistance of Helicobacter pylori, especially to clarithromycin is one of the main causes of failure of eradication.
- Trial name
- NCT01453036
- Testing
- 23S rRNA point mutation test of Helicobacter pylori, UBT test & Gastroenterology with biopsy c silver stain
- Where
- South Korea
- Volunteers
- 924 people, healthy volunteers welcome
- Sponsor
- Jin Il Kim
Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection
Background: A progressive decrease in Helicobacter pylori eradication rates has been described over the years, so new combinations of antibiotics for treatment are needed.
- Trial name
- R+OCA (NCT03124199)
- Testing
- Rifaximin
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Duodenal Ulcer
Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection
The purpose of this study is to demonstrate the non-inferior efficacy of TAK-438 versus lansoprazole in the treatment of participants with duodenal ulcer.
- Trial name
- NCT03050359
- Testing
- TAK-438, Lansoprazole, Bismuth-Containing Quadruple Therapy
- Where
- 81 sites in China, Philippines and 2 more
- Volunteers
- 533 people
- Sponsor
- Takeda
H. Pylori Infection
Patient-Centered Cancer Prevention In Chinese Americans
This study will assess the efficacy, adoption, and impact of an integrated intervention to improve adherence to recommended stomach cancer prevention guidelines (H. pylori test-and-treat) for at-risk Chinese Americans in NYC.
- Trial name
- NCT03340454
- Testing
- Test-and-treat EHR-CHW intervention, Usual care of EHR-only intervention
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- NYU Langone Health
Helicobacter Pylori Infection
Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients
Addition of L. reuteri to the standard triple therapy improves H. Pylori treatment outcomes.
- Trial name
- NCT01593592
- Testing
- Lactobacillus reuteri, Omeprazole, Amoxicillin
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Zagazig University
Helicobacter Pylori Infection
Comparison Between Quadruple Regimens for Helicobacter Pylori Infection in Egypt
The overall prevalence of H. Pylori in the developing countries is 50.8%, with the highest one presented in Africa (79.1%). Hybrid therapy is supposed to be more effective as a first-line regimen for Helicobacter pylori infection…
- Trial name
- NCT04039412
- Testing
- Hybrid regimen, Reverse hybrid regimen, Levofloxacin quadruple regimen
- Where
- Egypt
- Volunteers
- 330 people
- Sponsor
- Ayman Magd Eldin Mohammad Sadek
Helicobacter Pylori Infection
Levofloxacin Triple and Bismuth Quadruple Therapies for Rescue Treatment of H Pylori Infection
From the profiles of antibiotic susceptibility data following eradication therapy, tetracycline, amoxicillin and levofloxacin are all good candidates of antibiotics used in the rescue treatment.
- Trial name
- NCT02978157
- Testing
- esomeprazole+amox+levo, esomeprazole+bismuth+tetra+levo
- Where
- Taiwan
- Volunteers
- 102 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Helicobacter Pylori Infection
Concomitant, Sequential, and Standard Triple Therapy for H. Pylori Infection
To simultaneously compare the efficacies of 7-day triple, 10-day sequential and 7-day quadruple therapies for H. pylori infection in Taiwan. Consecutive H.
- Trial name
- NCT01769365
- Testing
- 7-day quadruple therapy, 10-day sequential therapy, 7-day standard triple therapy
- Where
- Taiwan
- Volunteers
- 307 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Helicobacter Pylori Infection
Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea
1. To compare 10-day sequential therapy and 14-day modified bismuth quadruple therapy and to establish more effective first-line regimen for the eradication of Helicobacter pylori in Korea. 2. To evaluate the effect of H.
- Trial name
- NCT02159976
- Testing
- Pantoprazole, Amoxicillin, Clarithromycin
- Where
- South Korea
- Volunteers
- 390 people
- Sponsor
- Seoul National University Bundang Hospital